PriMera Scientific Surgical
Research and Practice
Volume 8 Issue 5 November 2026
DOI: 10.56831/PSSRP-08-346
ISSN: 2836-0028

PriMera Scientific Publications

The Importance of Microbiome to Overall Health: Integrating Case Studies into improvement of Health and Wellness

Type: Case Study
Received: June 22, 2026
Published: November 03, 2026

Citation:
Christina Rahm. "The Importance of Microbiome to Overall Health: Integrating Case Studies into improvement of Health and Wellness". PriMera Scientific Surgical Research and Practice 8.5 (2026): 21-31.

Copyright:
© 2026 Christina Rahm. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Christina Rahm*

DRC VENTURES LLC, USA

***Corresponding Author:** Christina Rahm, DRC VENTURES LLC, USA.

Abstract

The "human microbiome" encompasses a vast community of microorganisms that reside on and inside the human body and play a vital role in promoting health and wellbeing. The microbiome aids in the digestive process metabolic functions, boosts immunity, and promotes mental health via pathways such as the gut-brain axis. On this note, any disruptions in the microbial imbalance, however, which is also referred to as dysbiosis, are associated with disorders like 'attention deficit hyperactivity disorder,' 'autism spectrum disorder,' and 'Alzheimer's disease.' This research paper explores the role of the microbiome in human health and well-being by integrating the case study findings with existing research to ascertain the therapeutic implications of microbiome-targeted interventions. The case studies involved here highlight the impact of proprietary blends, probiotics uses, and dietary modifications to help enhance emotional regulation, promote the sleep process, ability to focus, and the overall cognitive performance of patients with 'Alzheimer's,' 'attention deficit hyperactivity disorder (ADHD),' and 'autism spectrum disorder (ASD).' For example, the mini-mental status exam scores were shown to improve among Alzheimer's patients following the provision of microbiome-targeted therapies, which reflect better cognitive health and overall individual performance. The paper seeks to advocate for a need to increase access to microbiome-based interventions and policy adoption to promote their use in supporting healthcare for various patients. By leveraging the advancing findings in microbiome research today, it is possible to revolutionize treatment for complex disorders and promote the Health and wellbeing of patient populations.

Introduction

With the advances that have enabled whole genome sequencing in various organisms, the healthcare field has been able to acquire an exponential amount of genome sequencing information regarding various microorganisms. "Here, more than 130000 complete or near-complete bacterial genomes have been sequenced" (Aggarwal et al., 2022). "The human body is composed of a microbiome, which contains a collection of dynamic microbial communities that inhabit different anatomical areas in the body. In this case, the coevolution of such microbiomes in the host has led to such communities having a profound function in promoting human health and wellbeing" (Aggarwal et al., 2022). On this assertion, the perturbations on the microbiome can either cause, prevent, or even exacerbate

different diseases, which include mental issues such as Alzheimer's disease. The human microbiome comprises fungi, bacteria, and viruses, among other microbes, which reside in different parts, with the most densely populated area being the gastrointestinal tract.

Today, it is understood that the microbiome has a major role in maintaining human health by influencing different processes, including mental well-being, digestion, and immune function; where with the current advances in research, it has been established that a diverse and balanced microbiome is an integral component for optimal human health, while any imbalances result in a range of disorders like 'Alzheimer's disease,' 'attention deficit hyperactivity disorder,' and 'autism spectrum disorder' among others (Ceca-Ros et al., 2021). In particular, the gut microbiome is known to play an integral function in the human body's metabolic function, neurological processes, and immunological functions, which influences various processes, such as modulation of immune responses, nutrient absorption, and communication with the central nervous systems through the gut-brain axis (Lu et al., 2024). This forms a 'bidirectional communication network' that links gut health with emotional and cognitive wellbeing, hence, any disruptions in the gut-brain axis, in particular, lead to concerns like neurodevelopmental problems and neurodegenerative concerns.

The Need for Ensuring Microbial Balance

The microbial balance is important for human health and wellness, and factors such as diet, medications, environment, and lifestyle can influence the diversity of the microbial population; where, for example, an individual exposed to toxic metals, antibiotic regimen, and poor diet choices results in disrupted gut microbiota, thus compromising the gut barrier integrity. In this case, this results in a "leaky gut," which allows toxins to enter the bloodstream, hence triggering immune response and inflammatory processes. Based on this assertion, microbiome-targeted interventions, dietary change adoption, and the use of probiotics can be helpful in restoring the microbial balance, which has become a particular area of interest in current healthcare strategies. Various research on the microbiome has shifted from theoretical understanding to real-life practical applications; thus, advances in metagenomics and microbiome analysis have enhanced the research to establish the specific microbial strains that lead to a disease of health improvement. In this case, clinical interventions that target the microbiome have undergone exploration and continue to be researched to determine its usefulness as a treatment option for disorders like Alzheimer's disease, attention deficit and hyperactivity disorder, and autism spectrum disorder.

The research objective

This research aims to investigate the function of the microbiome in promoting the overall Health and wellbeing of human beings. The paper involves the latest research support from various literature sources, clinical trials, and case studies to offer a comprehensive understanding of the microbiome in the immune function, mental health, and metabolic balance. Through analyzing various case studies on Alzheimer's disease, ADHD, and autism disorder, the research paper will present how offering personalized intervention that targets the human microbiome can help to improve the health and wellbeing of individuals.

Case studies to support the role of the microbiome

To determine the role of microbiome-targeted therapy in promoting human health and wellbeing, three case studies, which include successful implementation of the interventions in real life will be involved. This includes a case of a 13-year-old Slovenian boy diagnosed with Autism Spectrum Disorder who experienced reduced anxiety scores, improved sleep, increased social engagement, and emotional control after a microbiome-targeted intervention. The other involves a 6-year-old boy diagnosed with ADHD who presented with significant improvement of sensory integration, focus, and emotional regulation after being offered a protocol combining omega-3s, proprietary blends, and diet changes to promote gut microbiome. The third case involves a 70-year-old woman and a 72-year-old man with Alzheimer's disease who were shown to have better memory recall, mood, and cognitive function after being offered personalized microbiome-focused interventions. In these cases, the scores from a mini mental status exam showed improvement signs reflecting better cognitive performance.

The role of the microbiome in Human Health

Basics of microbiome

The structure and functions of the microbiome

The microbiome presents with a vast community of microorganisms, which include the archaea, viruses, fungi, and bacteria that inhabit the human body, with the most prominent number being found in the human gut, especially in the large intestine. In the gut microbiome, there are about 100 trillion microorganisms, which outnumber the human body cell number by a ratio of 10:1 (Dupont et al., 2020). The primary role of the microbiome is to promote the homeostatic function in the human body, where each of these species contributes to a unique set of functions such as immune regulation, digestion process, and production of essential metabolites and vitamins (Hou et al., 2022). Some beneficial bacteria like the '*Bifidobacterium* and *Lactobacillus* 'play a vital role in gut function, while other pathogenic microbes like *Clostridium difficile* lead to gastrointestinal disorders in case of an imbalance or a disturbance in the microbial balance.

The key components of the microbiome

i. Commensal bacteria promote immune system function and gut health.
ii. Pathogenic bacteria that trigger infections and gut dysbiosis when not balanced with the commensal bacteria.
iii. Archaea, which play a vital digestion role, especially in breaking down complex carbohydrates.
iv. Fungi such as candida albicans can be pathogenic when they overgrow, causing fungal infections.
v. Viruses, while many tend to be pathogenic, some viral elements lead to microbial diversity and play a major role in promoting human health.




Figure 1: Showing the human microbiome in various locations in the gastrointestinal tract (Ruan et al., 2020).

Factors influencing microbial diversity

Microbial diversity indicates a range and abundance of different microorganisms in the human microbiome, which is a key indicator of health, whereas a more diverse microbiome results in better disease resilience. Some of the key factors that influence diversity include the diet, where meals rich in fiber lead to increased microbial diversity, while taking sugary and processed meals reduces it. The individual's age also affects the diversity, increasing from infancy to adulthood and reducing with ageing. Taking drugs like antibiotics also reduces microbial diversity by destroying beneficial bacteria. Finally, living a sedentary lifestyle, having poor sleep, and high stress can have a negative impact on microbial diversity in the human body (Martinez et al., 2021).

The major functions of the microbiome

One of the key functions of the human body microbiome involves improved digestive health and nutrient absorption (Oliphant et al., 2019). The microbiome is important in breaking down complex carbohydrates, fibers, and other indigestible food components where the beneficial microbes help produce short-chain fatty acids like propionate, acetate, butyrate, and acetate that support the gut barrier integrity and fuel the function of the colon cells (Rugrok et al., 2023). Some of the ways in which they contribute to the process include fiber fermentation into SCFAs that provide energy to the colon cells, enhance the synthesis of essential nutrients like vitamins B and K2, and get involved in enzyme production where the microbes form enzymes like cellulase, which the human body does not produce on itself (Anumudu et al., 2023). The microbiome also has a major function in immune modulation, where it modulates the immune system to discern between the foe and the friend organicism (Kogut et al., 2020). Here, the gut-associated lymphoid tissues (GALT), the largest body immune organ, rely on the signals from the microbiome to function appropriately (Bemark et al., 2024). In this case, the key contributions include barrier protection through a stronger gut barrier, immune tolerance, where exposure to commensal bacteria helps the immune system to tolerate nonpathogenic microbes, and immune signaling, where the microbiome modulates the immune signaling pathways, thus reducing inflammatory processes.

The microbiome also significantly impacts mental health through the gut-brain axis (Verma et al., 2024). The gut-brain axis presents as a bi-directional communication system that links the central nervous system with the gut microbiome (Toader et al., 2023). Here, the enteric nervous system of the gut contains more than 100 million neurons, sometimes called the second brain. The microbial contribution to brain health includes neurotransmitter production, which includes dopamine, serotonin, and gamma-aminobutyric acid, regulation of mood and behavior whereby any disruption in microbiome results in anxiety, depression, and neurodevelopmental disorder risks, and finally, neuroinflammation through dysbiosis, which trigger pro-inflammatory cytokines that affect the brain's health (Geng et al., 2022; Dicks, 2022).




Figure 2: Showing the gut and brain communication. Obtained from (Suganya & Koo, 2020).

The other function entails the microbiome involvement in metabolism and body weight management (Yarahmadi et al., 2024; Boscaini et al., 2022). The microbiome affects metabolic health and body weight, whereby some bacteria are associated with the extraction of energy from the food diet, and thus, the disruption of the balance of these bacteria may lead to obesity and other metabolic complications such as diabetes (Boscaini et al., 2022). Some of the key contributions to this function include the regulation of metabolism, whereby the microbiota influence the amount of calorie intake from the consumed food. SCFAs, short-chain fatty acids, are also used to generate energy and control metabolism (O'Riordan et al., 2022). Lastly, the microbiome has an impact on weight, and research has shown that obese people have a different composition of gut microbiota than non-obese people (Noor et al., 2023).

Microbial Interference

Impact of Diet and Lifestyle

Intake of a poor diet, which includes too much saturated fat, processed foods, and foods high in sugar, decreases the diversity, while foods high in fiber levels increase it. On the other hand, chronic stress interferes with the gut-brain axis to cause microbiome dysbiosis, which increases the disease risk. As well, lack of sleep also affects the gut microbiome, which can lead to chronic diseases such as diabetes and neurocognitive disorders.

Effects of Toxins and Heavy Metals

High exposure to chemicals such as lead, mercury, and cadmium affects microbial ecology and general wellbeing. Some of these effects affect the microbial processes, where the microbes remove toxic metals through processes such as oxidation, reduction, and methylation. On the Impact on Health, the heavy metals affect the gut barrier permeability and initiate immune response.

The Role of Parasites and Fungi on the Microbial Ecology

Exposure to parasites such as malaria and other parasitic infections affects microbiota diversity, immune signaling, and the gut barrier. For the Fungi, any overgrowth of Candida alters the microbial balance, forming biofilms that decrease microbial diversity. In the neurological system, some parasites and fungi are associated with neurodevelopmental disorders and cognitive decline (Postan & Rottenberg, 2021).

Case studies and analysis

Autism spectrum disorder and the microbiome

Autism spectrum disorder refers to a complex neurodevelopmental problem that presents with repetitive behaviors, impaired social interactions, and limited or restricted interests. This study, considering a case study of a 13-year-old boy from Slovenia, provides crucial light on the potential implication of microbiome-targeted interventions to help address symptoms associated with Autism. Here, the patients presented with symptoms such as persistent bed wetting, limited speech comprehensible only to the mother, severe sleep disturbances, and reduced social engagement. The child's behavior, in their case, was primarily limited to video games with minimal interest in exploring the external world. For this case, the boy was treated using proprietary blends that targeted detoxification (proprietary blend 1) and cognitive enhancement (proprietary blend II), which led to significant improvement within 5 months. Here, the patient's sleep quality improved dramatically over the first month, with nightmares and nocturnal enuresis ceased, which diminished by week 9. On the other hand, the patient manifested as having clearer speech and started engaging in activities such as assisting his mother and even singing. By month five, the patients showed increased physical activity, improved emotional regulation, and a notable anxiety reduction.

Such findings are in line with the emerging research evidence which has linked gut dysbiosis with Autism Spectrum Disorder. Evidence shows that children diagnosed with Autism Spectrum Disorder present with reduced levels of beneficial bacteria, which include the Lactobacillus and Bifidobacterium, and have an increase in the number of potentially dangerous bacteria such as Bacteroides and Clostridium (Mihailovich et al., 2023). The researcher notes that environmental exposure during fetal development, including metabolic status, maternal infection, and diet, interferes with brain development and promotes the development of Autistic traits, showing the complex relationship between exposure to the environment, maternal gut microbiome, and the offspring outcomes. In this case, maternal dysbiosis results in undesirable outcomes for the fetus and the mother's wellbeing (Mihailovich et al., 2023; Taniya et al., 2022). Here, such microbial imbalance tends to disrupt the gut-brain axis, which is the bidirectional communication system that is at the core of the emotional regulation and neurodevelopment of the child. Dysbiosis also tends to impair short-chain fatty acid production, which is important in preventing gut barriers and promoting anti-inflammatory effects, whereby research shows that restoration of the microbial balance using prebiotics, probiotics, and dietary interventions can help to enhance emotional control, reduce gastrointestinal symptoms, and improve the social behavior of a child (Markowiak-Kopec et al., 2020; Bear et al., 2020). In this case, the case

study supports the findings by showing how offering targeted interventions to autistic children can help address the key symptoms affecting the patients by utilizing the role of microbiome in gut-brain axis communication, hence by combining cognitive support with detoxification for autistic patients can create a very effective approach to address future therapeutic strategies for the disorder.

Microbiota imbalances, Attention Deficit Hyperactivity Disorder

Today, ADHD has been found to affect millions of worldwide children population who manifest with emotional dysregulation, impulsiveness, inattention, and hyperactivity; hence to explore the relationship between microbiota imbalance and improved health and well-being, we consider the case of Slovenian 6-year-old boy whose case highlights the critical function of microbiome-targeted interventions in helping to manage ADHD clinical features. In this case study, the child presented with critical features of ADHD, which included difficulty socializing and self-injurious practices like headbanging, and he was also severely hyperactive. On top of this, the picky feeding habits and the occurrence of keratosis pilaris showed that he had nutritional deficiencies and an underlying dysbiosis. For the patient, the treatment protocol involves proprietary blends for detoxification (proprietary blend I) and neurotransmitter modulation (proprietary blend II), as well as a specialized diet plan that was aimed at supporting the gut-brain axis associated with the disorder being able to achieve striking results, whereby after two months, the child manifested improved emotional regulation and reduced hyperactivity while also having empathy episodes emerging for the first time in his lifetime. At four months, the boy's sensory sensitivities reduced, which allowed him to wear clothes like jeans, which were previously uncomfortable, while at the eighth month, the teachers for the patient stated that he was symptom-free, showing normalized attention levels, social interaction, and emotional balance.

To support the case study findings, various scientific literature has been established to support the outcomes that highlight the role of the microbiome in the production of neurotransmitters (Mhanna et al., 2023). On this note, the gut microbiota has been found to produce critical compounds such as dopamine, serotonin, and gamma-aminobutyric acid, all of which are essential players in regulating behavior, focus, and mood. According to Mhanna et al. (2023), the gut microbiota plays a very integral role in the human body, influencing its wellbeing, where the gut-brain axis presents a communication network that is based on the neuroendocrine, neuronal, and immunological pathways. Here, the chemical substances, including the neurotransmitters and the short-chain fatty acids from the gut microbiota, have a direct influence on brain function levels (Kim & Shim, 2022). The dysbiosis associated with attention deficit hyperactivity disorder patients is linked with reduced microbial diversity and altered SCFA production, which leads to impaired cognitive function and exacerbated inflammation. There is also evidence to support the need to adopt an appropriate diet, which helps promote microbial diversity and short-chain fatty acid production and helps stabilize the neurotransmitter pathways that play a vital role in conditions like ADHD. Taking a specific example of the dopamine neurotransmitter, which plays a vital role in mood regulation, there has been a close relationship between the gut microbiota and the neurotransmitter effectiveness. Here, the neurotransmitter plays a role in activity execution, mood, mobility, excitement, and learning through reward. The link is based on the strong relationship between dopamine and gut microbiome, where various gut microorganisms have a neuroprotective effect on the dopamine neurons, thus reducing the dopamine depletion rate (Mhanna et al., 2023). It is important to consider the core impact on the activation of the inflammatory response through the endotoxins, which leads to dopamine depletion. For instance, a microorganism like lactobacillus case can help increase the levels of monoamine dopamine, norepinephrine, and serotonin in the frontal lobes of the brain (Mhanna et al., 2023). The case study outcomes and the evidence from research underscore the need to consider the therapeutic impact of microbiome-targeted interventions in helping manage the ADHD population today. By offering the patients a combination of both dietary adjustments with the proprietary blends, the child was able to not only have the symptoms alleviated but also have a long-term improvement noted. Such findings also support the need to consider the microbiome as a core component of the management of attention deficit hyperactivity disorder and other related neurodevelopmental disorders like autism.

Category	*Autism (ASD)*	*ADHD*
Patient Profile	13-year old boy, Slovenia	6-year old boy, Slovenia
Key Symptoms	Limited speech,sleep disturbances, bedwetting, anxiety, and reduced social interaction	Hyperactivity, impulsivity, self-injury, sensory sensitivity, social difficulty
Associated Factors	Gut dysbiosis, impaired gut brain axis	Gut dysbiosis, nutritional deficiencies, keratosis pilaris
Intervention	Proprietary Blend I (detoxification) + Proprietary Blend II (cognitive support)	Proprietary Blend I (detoxification) + Proprietary Blend II (neurotransmitter modulation) + diet
Timeline of Improvement	Sleep improved within 1 month; speech and engagement improved by month 5	Emotional regulation improved by 2 months; symptom-free by 8 months
Clinical Outcomes	Improved sleep, speech clarity, emotional regulation, reduced anxiety	Normalized attention, reduced sensory issues, improved social behavior
Mechanistic Insight	Restoration of microbiome balance supports gut–brain axis and emotional regulation	Microbiome supports neurotransmitter production (dopamine, serotonin, GABA)
Conclusion	Microbiome-targeted therapy may improve neurobehavioral symptoms in ASD	Microbiome-targeted therapy may normalize attention and behavior in ADHD

Table 1: Case Studies for Autism and ADHD.

Alzheimer's disease and the microbiome modulation

Alzheimer's disease refers to a neurodegenerative disorder that is progressive in nature, which remains a major cause of memory loss and cognitive performance decline among the aging population. To help explore the impact of the human microbiome in the promotion of Mental Health among individuals, two cases involving a 70-year-old woman and a 72-year-old man from Hungary were involved; whereby the cases show that microbiome-targeted therapies have a promising role in helping to mitigate the symptoms associated with Alzheimer's disease. Among the female patients, the mini-mental status exam score was 22, which showed mild dementia, while the male patient had a score of 19, which presented a moderate dementia problem, after which the two patients underwent comprehensive treatment protocols, including the provision of proprietary blends to help restore the patient's gut integrity, modulate the neurotransmitter pathways, and reduce the neuroinflammation processes. Following the initiation of the intervention, the female patient's family was able to report a noticeable improvement in mood, speech, and memory within a two-month period; and at the fourth month, the mini-mental status exam score was 26, which reflected an improvement from mild dementia towards normal cognitive function levels. Among the male patients, there was also significant improvement noted, with the MMSE improving to 24, with the family reporting that he had experienced better recall, enhanced mood, and a very exemptional daily activity engagement process. In this case, the reliance on the medications meant for dementia was reduced, which suggested that the microbiome-targeted therapy had helped to solve the underlying pathological processes, which is a core indicator to support the need for intervention in the management of Alzheimer's disease.

Such findings align with evidence regarding the effect of the gut axis on Alzheimer's disease. In this case, any alteration involving the gut microbiota composition leads to increased permeability of the gut barrier and the activation of the immune system, which leads to systemic inflammation, in turn impairing the blood-brain barrier and causing neuroinflammation, neuro injury, and even worse situations, neurodegeneration (Kowalski & Mulak, 2019). The chronic neuroinflammation which results here is considered a hallmark feature of Alzheimer's pathology. Also, gut microbes have a significant role in relation to amyloid plagues and other conditions exacerbating their accumulation in the brain. The gut microbiome and the microglia have a core role in this situation where elevated Bacteroides are associated with increased tau and amyloid-β in the cerebrospinal fluid among Alzheimer's disease patients. In an example of a study conducted by Wasen et al. (2024), which hypothesized that Bacteroides leads to Alzheimer's disease through microglia

modulation, the research found that administering Bacteroides fragilis to the PS1-21/APP mice leads to increased Aβ plaques levels in females, down-regulate the phagocytosis and protein degradation microglia gene expression, and modulate the cortical amyloid processing genetic expression. As well the study also depicted that using metronidazole to deplete the murine bacteroideta leads to decreased amyloid load for aged 5xFAD mice while also activating the microglial pathways associated with lysosomal degradation, cytokine signaling, and phagocytosis (Wasen et al., 2024). In this case, taking initiatives to engage such patients in microbiome-targeted intervention can help rebalance the microbial communities, thus enhancing the blood-brain barrier integrity and reducing neuroinflammation.

From the case studies and evidence obtained from the literature search, there is compelling evidence of the impact of the human body's microbiome on cognitive health, which is a critical component of overall health and well-being. Here, the observed improved mini-mental screening exam scores and the improved patient quality of life signify the need to validate the adoption of microbiome-targeted therapies as adjunct interventions to traditional Alzheimer's disease treatment. Also, due to limited research exploration on the topic, it is integral to conduct the interventions, especially in large clinical trials, which can help determine the scalability and efficacy levels.

Category	***Case 1***	***Case 2***
Patient Profile	70-year old female, Hungary	72-year old female, Hungary
Baseline Cognitive Status	Mild Dementia	Moderate Dementia
Baseline MMSE Score	22	19
Key Symptoms	Memory loss, mood changes, speech difficulty	Impaired recall, reduced daily functioning, mood changes
Underlying Factors	Suspected gut dysbiosis, neuroinflammation	Suspected gut dysbiosis, neuroinflammation
Intervention Strategy	Proprietary microbiome-targeted blends for gut integrity, neurotransmitter modulation, and neuroinflammation reduction	Proprietary microbiome-targeted blends for gut integrity, neurotransmitter modulation, and neuroinflammation reduction
Timeline of Improvement	Noticeable improvements within 2 months	Gradual improvement over several months
Clinical Outcomes	Improved mood, speech, and memory	Improved recall, mood, and daily activity engagement
Follow-up MMSE Score	26 (near-normall cognitive range)	24 (Improved cognitive function)
Medication Dependence	Reduced reliance on dementia medications	Reduced reliance on dementia medications
Proposed Mechanism	Microbiome rebalancing reduced gut permeability, systemic inflammation, and neuroinflammation	Microbiome modulation improved gut–brain axis signaling and reduced inflammatory burden
Conclusion	Microbiome-targeted therapy supported cognitive improvement and quality of life	Microbiome-targeted therapy supported cognitive improvement and functional engagement

Table 2: Case studies for Alzheimer's disease.

The Cost Considerations for the microbiome-informed intervention

Integrating microbiome-based interventions in healthcare based on the case studies presents a remarkable ability to achieve enormous health benefits among patients with mental issues like autism spectrum disorder, Alzheimer's disease, and ADHD. Despite these benefits, it is important to consider the financial implications of the therapies from the patient's perspective and consider the wider healthcare system.

Individual cost

For the patients, the proprietary blends used in the case studies (blends I-VI) were comprised of high-quality ingredients such as curcumin, N-acetyl L-tyrosine, vitamin C, and silica, among others, with a monthly cost ranging from around $200 to $500 per patient based on the dose given and the number of prescribed blends. For instance, the 13-year-old body diagnosed with autism spectrum disorder needed a dose increment for blend I (clean slate) and blend II (zero-in) in five months, which led to an estimated cost of about $1000 to $2500. As well, for the patient with ADHD, the patient was involved in microbiome-targeted supplements and dietary adjustments for 8 months with an approximate cost of $1500 to $3000. Among the patients with Alzheimer's disease, where the treatment was done with six proprietary blends given for 4 months, the cost per patient ranged from $2000 to $4000, considering the duration and intensity of the intervention. In this case, the costs are competitive compared to the current treatment measures for Alzheimer's disorder, which can go beyond $500 per month, especially when involving a combination of memory care expenses with caregiver support.

The healthcare system cost

On the system level, the cost to implement the microbiome-based intervention is substantial where, for example, clinical trials are needed to help validate the proprietary blends, which calls for a significant amount of investment. Based on the anticipated cost, a trial for about 1000 patients may need around $6.5 million, including quality assurance, regulatory approval, personnel expenses, and genetic testing. While there is an existing upfront cost, the potential to reduce the long-run experiences for chronic illness management offsets the investment incurred. An example is that offering timely microbiome intervention can help prevent disease progression, thus reducing the need for medical care in hospital facilities, which could be more demanding.

Conclusion and Recommendations

In conclusion, the human microbiome contains a complex ecosystem of microorganisms that play an integral role in health maintenance, metabolism, immunity, digestion, and improving mental health and wellbeing. The paper involves a discussion of the potential microbiome-targeted interventions to help in the management of Alzheimer's disease, attention deficit hyperactivity disorder, and autism spectrum disorder. Through a thorough case analysis, the research paper showcases the use and impact of such interventions to achieve better patient outcomes and clinical improvements in physical, emotional, and cognitive wellbeing. The case of the 13-year-old boy diagnosed with autism showed substantial progress in speech clarity, bladder control, sleep potential, and social engagement within 5 months of intervention after being offered proprietary blends that targeted cognitive enhancement and detoxification. Also, the 6-year-old boy diagnosed with attention deficit hyperactivity disorder presented with improved focus, reduced hyperactivity, and better sensory integration after 8 months of microbiome-focused protocol offered. For Alzheimer's disease, two patients demonstrated high improvement in mini-mental status examination scores, which involved cognitive function, mood, and memory function following 4 months of treatment. Such findings are efficient in supporting the transforming capacity of microbiome-targeted interventions.

Recommendations

To help maximize the effectiveness and use of microbiome-targeted interventions and solve any current barriers, it is important to:

i. Expand research and clinical trials on microbiome intervention through more large-scale randomized clinical trials to help determine microbiome-targeted interventions' safety and efficacy levels. Such trials need to be done in different populations to help

account for individual differences in the microbiome composition and control levels.

ii. Ensure affordability and accessibility of the intervention by considering the high cost, which could be a significant barrier to achieving widespread of the intervention adoption for microbiome-related interventions; the policymakers and health organizations need to advocate for insurance coverage in prebiotics, personalized microbiome therapies, probiotics, among others to ease the financial burden experienced by the patients.

iii. Engage in early interventions. Timely microbiome intervention, especially among children with disorders like Attention Deficit Hyperactivity Disorder and Autism, helps minimize the likelihood of longer complications, emphasizing the role of public health programs in sustaining the need for microbial diversity and diet from infancy to adulthood.

iv. Inclusion of personalized medicine. In healthcare, advances in microbiome mapping and metagenomics provide a chance to help tailor microbiome-targeted therapies to individual needs. As such, the healthcare system needs to adopt such technologies to develop more customized treatment plans for individuals diagnosed with complex disorders.

v. Education among healthcare professionals through training programs will help them incorporate microbiome science and promote their understanding of the impact of therapy on the control of different chronic conditions.

This way, microbiome-based interventions show a paradigm shift in the healthcare sector, providing a holistic shift in managing both neurodegenerative and neurodevelopmental conditions; thus, by responding to research gaps, access, and cost containment, such interventions make it possible to achieve wider integration in mainstream medicine, thus improving clinical and overall health and wellbeing for millions of global individuals.

References

1. Aggarwal N., et al. "Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies". Chemical Reviews 123.1 (2022): 31.
2. Anumudu CK, Miri T and Onyeaka H. "Multifunctional Applications of Lactic Acid Bacteria: Enhancing Safety, Quality, and Nutritional Value in Foods and Fermented Beverages". Foods 13.23 (2023): 3714.
3. Bear TLK., et al. "The Role of the Gut Microbiota in Dietary Interventions for Depression and Anxiety". Advances in Nutrition 11.4 (2020): 890-907.
4. Bemark M., et al. "Gut-associated lymphoid tissue: A microbiota-driven hub of B cell immunity". Trends in Immunology 45.3 (2024): 211-223.
5. Boscaini S., et al. "Microbiota and body weight control: Weight Watchers within?" Molecular Metabolism 57 (2022): 101427.
6. Checa-Ros A., et al. "Current Evidence on the Role of the Gut Microbiome in ADHD Pathophysiology and Therapeutic Implications". Nutrients 13.1 (2021): 249.
7. Dicks LMT. "Gut Bacteria and Neurotransmitters". Microorganisms 10.9 (2022): 1838.
8. Dupont HL., et al. "The Intestinal Microbiome in Human Health and Disease". Transactions of the American Clinical and Climatological Association 131 (2020): 178-197.
9. Geng H., et al. "Enteric Nervous System: The Bridge Between the Gut Microbiota and Neurological Disorders". Frontiers in Aging Neuroscience 14 (2022): 810483.
10. Hou K., et al. "Microbiota in Health and Diseases". Signal Transduction and Targeted Therapy 7.1 (2022): 1-28.
11. Kim H and Shim O. "Gut microbiota affect brain development and behavior". Clinical and Experimental Pediatrics 66.7 (2022): 274.
12. Kogut MH, Lee A and Santin E. "Microbiome and pathogen interaction with the immune system". Poultry Science 99.4 (2020): 1906-1913.
13. Kowalski K and Mulak A. "Brain-Gut-Microbiota Axis in Alzheimer's Disease". Journal of Neurogastroenterology and Motility 25.1 (2019): 48-60.
14. Lu S., et al. "The communication mechanism of the gut-brain axis and its effect on central nervous system diseases: A systematic review". Biomedicine & Pharmacotherapy 178 (2024): 117207.

15. Markowiak-Kopeć P and Śliżewska K. "The Effect of Probiotics on the Production of Short-Chain Fatty Acids by Human Intestinal Microbiome". Nutrients 12.4 (2020): 1107.
16. Martinez JE., et al. "Unhealthy Lifestyle and Gut Dysbiosis: A Better Understanding of the Effects of Poor Diet and Nicotine on the Intestinal Microbiome". Frontiers in Endocrinology 12 (2021): 667066.
17. Mihailovich M., et al. "The Microbiome-Genetics Axis in Autism Spectrum Disorders: A Probiotic Perspective". International Journal of Molecular Sciences 25.22 (2023): 12407.
18. Mhanna A., et al. "The correlation between gut microbiota and neurotransmitters and mental disorders: A narrative review". Medicine 103.5 (2023): e37114.
19. Noor J, Chaudhry A, Batool S, Noor R and Fatima G. "Exploring the Impact of the Gut Microbiome on Obesity and Weight Loss: A Review Article". Cureus 15.6 (2023): e40948.
20. Oliphant K and Allen-Vercoe E. "Macronutrient metabolism by the human gut microbiome: Major fermentation by-products and their impact on host health". Microbiome 7 (2019): 91.
21. O'Riordan KJ., et al. "Short-chain fatty acids: Microbial metabolites for gut-brain axis signaling". Molecular and Cellular Endocrinology 546 (2022): 111572.
22. Postan M and Rottenberg ME. "Editorial: Neurotropism of Parasites and the Immune Responses". Frontiers in Immunology 12 (2021): 775666.
23. Ruan W., et al. "Healthy Human Gastrointestinal Microbiome: Composition and Function After a Decade of Exploration". Digestive Diseases and Sciences 65.3 (2020): 695-705.
24. Ruigrok RAAA, Weersma RK and Vich Vila A. "The emerging role of the small intestinal microbiota in human Health and disease". Gut Microbes 15.1 (2023).
25. Suganya K and Koo B. "Gut-Brain Axis: Role of Gut Microbiota on Neurological Disorders and How Probiotics/Prebiotics Beneficially Modulate Microbial and Immune Pathways to Improve Brain Functions". International Journal of Molecular Sciences 21.20 (2020): 7551.
26. Taniya MA., et al. "Role of Gut Microbiome in Autism Spectrum Disorder and Its Therapeutic Regulation". Frontiers in Cellular and Infection Microbiology 12 (2022): 915701.
27. Toader C., et al. "Mind, Mood, and Microbiota—Gut-Brain Axis in Psychiatric Disorders". International Journal of Molecular Sciences 25.6 (2023): 3340.
28. Verma A, Inslicht SS and Bhargava A. "Gut-Brain Axis: Role of Microbiome, Metabolomics, Hormones, and Stress in Mental Health Disorders". Cells 13.17 (2023): 1436.
29. Wasén C., et al. "Bacteroidota inhibits microglia clearance of amyloid-beta and promotes plaque deposition in Alzheimer's disease mouse models". Nature Communications 15.1 (2024): 1-12.
30. Yarahmadi A., et al. "Understanding the complex function of gut microbiota: Its impact on the pathogenesis of obesity and beyond: A comprehensive review". Diabetology & Metabolic Syndrome 16 (2024): 308.